<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546818</url>
  </required_header>
  <id_info>
    <org_study_id>SAV-CT01</org_study_id>
    <nct_id>NCT01546818</nct_id>
  </id_info>
  <brief_title>Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients</brief_title>
  <official_title>A Phase I, Randomized, Observer-blinded, Placebo-controlled Clinical Study to Assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumagen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety, tolerability, and immune response to&#xD;
      killed-whole HIV-1 (SAV001-H) vaccine as a primary vaccination regimen in HIV infected&#xD;
      individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of at least one Grade 3 or higher adverse event, including signs/symptoms, lab toxicities, and/or clinical events possibly or definitely related to study treatment</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immune response of killed-whole HIV-1 (SAV001-H) administered intramuscularly in individuals with chronic HIV-1 infection on HAART</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SAV001-H</intervention_name>
    <description>A whole-killed HIV</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infected&#xD;
&#xD;
          -  Chronic HIV infection as defined by documentation of HIV infection for over ne year.&#xD;
&#xD;
          -  Prior antiretroviral therapy defined as a minimum of 6 months of treatment with HAART.&#xD;
             (HAART is defined as a combination of at least 2 antiretroviral agents.)&#xD;
&#xD;
          -  CD4+ cell count more than 350 cells per mm3 for a period of 6 months prior to study&#xD;
             entry at least at 3 different time points (one of which must be obtained at screening)&#xD;
             obtained at any laboratory that possesses a CLIA certification or its equivalent.&#xD;
&#xD;
          -  HIV-1 RNA levels less than 50 copies per mL for a period of 6 months prior to study&#xD;
             entry at least at 3 different time points (one of which must be obtained at screening)&#xD;
             by any laboratory that possesses a CLIA certification or its equivalent.&#xD;
&#xD;
          -  Laboratory values obtained within 28 days prior to study entry&#xD;
&#xD;
          -  Men and women between 18 and 50 years of age&#xD;
&#xD;
          -  Female study volunteers of reproductive potential (defined as girls who have reached&#xD;
             menarche or women who have not been post-menopausal for at least 24 consecutive&#xD;
             months, i.e. who have had menses within the preceding 24 months, or have not undergone&#xD;
             surgical sterilization (e.g. hysterectomy, bilateral oophorectomy, or salpingotomy)&#xD;
             must have a negative serum or urine pregnancy test performed within 3 days before&#xD;
             initiating study-specified medication.&#xD;
&#xD;
        If participating in sexual activity that could lead to pregnancy, the female study&#xD;
        volunteer must use a form of contraception listed below while receiving protocol-specified&#xD;
        medication and for 6 months after stopping the medication. At least one of the following&#xD;
        methods MUST be used appropriately (with or without hormone-based method):&#xD;
&#xD;
          -  Condoms (male or female) with or without a spermicidal agent&#xD;
&#xD;
          -  Diaphragm or cervical cap with spermicide&#xD;
&#xD;
          -  IUD&#xD;
&#xD;
               -  Informed of, and willing and able to comply with, the investigational nature of&#xD;
                  the study, and have signed an informed consent form in accordance with&#xD;
                  institutional and regulatory guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of serious adverse reactions to vaccines including anaphylaxis and related&#xD;
             symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain,&#xD;
             except for subjects who have a history of an adverse reaction to pertussis vaccine as&#xD;
             a child may enroll.&#xD;
&#xD;
          -  History of CD4+ counts less than 350 cells per mm3, opportunistic infections, or&#xD;
             AIDS-defining illnesses.&#xD;
&#xD;
          -  History of autoimmune disease, immunodeficiency (other than HIV infection), asthma,&#xD;
             diabetes (including Type II diabetes or insulin resistance) requiring insulin or oral&#xD;
             hypoglycemics, thyroid disease, bleeding disorder, active malignancy, viral hepatitis,&#xD;
             or asplenia.&#xD;
&#xD;
          -  HBVsAg, HCV Ab, or RPR positive.&#xD;
&#xD;
          -  Suspected allergy or adverse reaction to any components of the study agent.&#xD;
&#xD;
          -  Changes in antiretroviral regimen within 6 months prior to entry due to virologic&#xD;
             failure (not including toxicities).&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
&#xD;
          -  Receipt of live attenuated vaccines or investigational research agents within 30 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Receipt of blood products within 120 days prior to study entry.&#xD;
&#xD;
          -  Receipt of immunoglobulin within 60 days prior to study entry.&#xD;
&#xD;
          -  Receipt of medically indicated subunit or killed vaccines (e.g., influenza,&#xD;
             pneumococcal, or allergy treatment with antigen injections) within 14 days prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Receipt of prior experimental HIV vaccines.&#xD;
&#xD;
          -  Any investigational antiretroviral agents that are not obtained through expanded&#xD;
             access.&#xD;
&#xD;
          -  Receipt of immunosuppressive medications within the past 6 months (e.g.,&#xD;
             oral/parenteral/inhaled corticosteroids, and/or cytotoxic medications). NOTE: The&#xD;
             following will be allowed: corticosteroid nasal spray for allergic rhinitis; topical&#xD;
             corticosteroids for acute, uncomplicated dermatitis; over the counter medications for&#xD;
             acute, uncomplicated dermatitis for a period not longer than 14 days.&#xD;
&#xD;
          -  Current anti-TB prophylaxis or therapy.&#xD;
&#xD;
          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,&#xD;
             would interfere with adherence to study requirements.&#xD;
&#xD;
          -  Serious illness (requiring systemic treatment and/or hospitalization) until subject&#xD;
             either completes therapy or is clinically stable on therapy, in the opinion of the&#xD;
             investigator, for at least 14 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony M Mills, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anthony Mills MD Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Schneider, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Living Hope Clinical Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anthony Mills, MD Internal Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>September 5, 2013</last_update_submitted>
  <last_update_submitted_qc>September 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Vaccine</keyword>
  <keyword>HIV-1 infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

